Delayed Onset of Pulmonary Hypertension Associated With an Appetite Suppressant, Mazindol. A Case Report.
| Accession number;00A0262846 |
| Title;Delayed Onset of Pulmonary Hypertension Associated With an Appetite Suppressant, Mazindol. A Case Report. |
| Author;HAGIWARA M(Sapporo Medical Univ. School Of Medicine, Sapporo, Jpn) TSUCHIDA A(Sapporo Medical Univ. School Of Medicine, Sapporo, Jpn) HYAKKOKU M(Sapporo Medical Univ. School Of Medicine, Sapporo, Jpn) NISHIZATO K(Sapporo Medical Univ. School Of Medicine, Sapporo, Jpn) ASAI T(Sapporo Medical Univ. School Of Medicine, Sapporo, Jpn) NOZAWA Y(Sapporo Medical Univ. School Of Medicine, Sapporo, Jpn) TSUCHIHASHI K(Sapporo Medical Univ. School Of Medicine, Sapporo, Jpn) SHIMAMOTO K(Sapporo Medical Univ. School Of Medicine, Sapporo, Jpn) |
Journal Title;Jpn Circ J
|
Journal Code:F0908A
|
ISSN:0047-1828
|
|
VOL.64;NO.3;PAGE.218-221(2000)
|
| Figure&Table&Reference;FIG.5, REF.8 |
| Pub. Country;Japan |
| Language;English |
| Abstract;The use of the appetite suppressant agents aminorex and fenfluramine derivatives has been reported as a risk factor for the development of pulmonary hypertension. A 29-year-old female developed pulmonary hypertension suspected to be due to an amphetamine-like appetite suppressant agent, mazindol ((.+-.)-5-(p-chlorophenyl)-2,5-dihydro-3H-imidazo [2,1-a] isoindol-5-ol). She was admitted to Sapporo Medical University Hospital with dyspnea due to severe pulmonary hypertension. Twelve months prior to admission, she had taken mazindol continuously for a period of 10 weeks. As yet, her pulmonary hypertension has not completely improved. This is the first reported case of mazindol-associated pulmonary hypertension, which developed after a long latent interval, and it suggests that mazindol is also a risk factor for the development of pulmonary hypertension, making long-term follow-up necessary for patients taking this anorectic agent. (author abst.) |
|
|
